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Background: Erlotinib showed anti-tumor activity in patients
with previously-treated advanced NSCLC, especially in female
gender, never smokers and adenocarcinoma histology. Recent
analyses have reported that mutations in the EGFR tyrosine kinasi
domain underlie responsiveness to erlotinib.
We investigated HER1/EGFR gene mutations as potential pre-
dictive markers of clinical benefit with erlotinib.
Methods: From01-01-06 to 31-12-06wehaveobserved54women
with stage IIIb/IVadenocarcinoma and selected 32 ( 59.25%) on the
basis of available tumor tissue.
Exons 19 and 21 of the EGFR TK domain were found mutated
by direct sequencing in 9 (28% of selected). Erlotinib was admin-
istered in 18 (56.25% of selected) patients (pts), never smokers
(150 mg/die until disease progression or inacceptable toxicity), 7
mutated (38.8% of treated) and 11 not.
Results: The median age of the 18 pts was 61 years (range 58–
74). Median ECOG PS was 1 (range 0–1). After 8 weeks of treat-
ment, of 7 patients with mutations the disease control rate
(CR + PR + SD) was 100% with 1 CR, 4 PR, 2 SD and no PD, while
of 11 women without mutations, disease control rate was 81.8%
(9 pts) with, 1 CR, 2 PR, 6 SD and 2 PD.
Time to progression (TTP) of patients with of without muta-
tions were 7.7 months and 5 months, respectively.
Conclusions: These preliminary data coming from clinical prac-
tice, confirm the efficacy of erlotinib in never smokers, adenocar-
cinoma and female and the non correlation of EGFR mutations
with sensitivity to erlotinib. Therefore similar TTP was observed
between pts with or without mutations. The biological mecha-
nism of these EGFR mutations to the response remains to evalu-
ate in future study.
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